{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-015307","form_type":"8-K/A","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.979746+00:00","generated_at":"2026-05-15T05:26:58.045930+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Gyre Therapeutics amends 8-K to correct Cullgen stock conversion terms in $300M acquisition","bullets":["Amendment fixes clerical error in original March 2, 2026 8-K describing stock conversion for Cullgen holders.","Designated Cullgen shareholders receive Series B Convertible Preferred, convertible into 5 Gyre common shares each.","Other Cullgen holders receive Gyre common stock at exchange ratio of 0.4753 per Cullgen share.","All-stock deal values Cullgen at ~$300 million; no substantive changes to merger agreement beyond correction."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-015307","json":"https://secwatch.observer/filing/0001140361-26-015307.json","markdown":"https://secwatch.observer/filing/0001140361-26-015307.md","text":"https://secwatch.observer/filing/0001140361-26-015307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126015307/0001140361-26-015307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126015307/ef20070667_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:26:58.045930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}